MedTrace Logo

Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01289015 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 855

Last updated 2013-09-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of NAFT-600, applied once daily for 2 weeks, when compared to placebo for 2 weeks in the treatment of subjects with tinea pedis.

Conditions

  • Tinea Pedis

Interventions

DRUG

NAFT-600 ( naftin 2 % gel )

Topical; applied once daily for two weeks

DRUG

Placebo

Topical; applied once daily for two weeks

Sponsors & Collaborators

  • Merz North America, Inc.

    lead INDUSTRY

Principal Investigators

  • Lawrence Parish, MD · Paddington Testing Co., Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-11-30
Completion
2012-01-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289015 on ClinicalTrials.gov